Procter & Gamble’s Actonel osteoporosis drug is expanding its potential audience among men. The Food and Drug Administration has approved Actonel's once-a-week version to help increase bone mass in men with osteoporosis. Previously, Actonel had been approved to treat the disease in postmenopausal women and in men with steroid-induced osteoporosis. The approval is another step forward for Actonel, the only pharmaceutical product among the 22 P&G brands with more than $1 billion in annual sales. (Read more in the Enquirer)